article thumbnail

J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey

Fierce Pharma

Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)

article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What if Bill Clinton & Ronald Reagan Had Debates Universal Government Funded Healthcare? A Fictional Debate Portrayal.

Pharma Marketing Network

Bill Clinton: My fellow Americans, I stand here today to argue in favor of universal government-funded healthcare. Furthermore, universal government-funded healthcare would help to level the playing field for all Americans, regardless of their socioeconomic status. Ronald Reagan: My fellow Americans, I must disagree with my colleague.

article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Big Pharma’s chokehold around the U.S. Via Axios “The 10 highest-selling drugs in the U.S.

Pharma 241
article thumbnail

Financial factors to support and challenge Pharma in 2024

European Pharmaceutical Review

Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024. The report recommened that to gain a competitive edge in the market, focusing on modernising R&D models or implementing emerging technologies could support this endeavour.

Pharma 76
article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. billion (around $4 billion) in revenue to the government – 26.5% billion (around $4 billion) in revenue to the government – 26.5%

Pharma 70